title: Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results.
abstract: OBJECTIVE
  To compare the effect of photodynamic therapy (PDT) and intravitreal ranibizumab in patients with polypoidal choroidal vasculopathy (PCV).
  
  
  METHODS
  Randomized clinical trial.
  
  
  METHODS
  
  
  
  METHODS
  Multicenter.
  
  
  METHODS
  Total of 93 patients with treatment-naïve PCV.
  
  
  METHODS
  Patients were randomized to 2 arms. Patients in the PDT arm underwent a single session of PDT with verteporfin, and patients in the ranibizumab arm received 3 monthly ranibizumab injections at baseline. Additional treatment was performed as needed in each arm.
  
  
  METHODS
  Primary outcome measurement was the proportion of patients gaining or losing more than 0.2 logarithm of minimal angle of resolution (logMAR) units from baseline. Mean change of logMAR and central retinal thickness (CRT) were also evaluated.
  
  
  RESULTS
  In the PDT arm (n = 47), 17.0% achieved visual acuity gain, 55.3% had no change, and 27.7% experienced visual acuity loss. The results were 30.4%, 60.9%, and 8.7%, respectively, in the ranibizumab arm (n = 46), significantly better than the PDT arm (P = .039). In the PDT arm, mean CRT improved (366.8 ± 113.6 μm to 289.1 ± 202.3 μm, P < .001), but logMAR was unchanged (0.57 ± 0.31 to 0.62 ± 0.40). The ranibizumab arm demonstrated improvement in both CRT (418.9 ± 168.6 μm to 311.2 ± 146.9 μm, P < .001) and logMAR (0.48 ± 0.27 to 0.39 ± 0.26, P = .003). Mean change of logMAR was also greater in the ranibizumab arm (P = .011).
  
  
  CONCLUSIONS
  Intravitreal injection of ranibizumab is more effective than PDT for treatment-naïve PCV.
authors.affiliation: Kobe City Medical Center General Hospital, Kobe, Japan. Electronic address: aquio@kuhp.kyoto-u.ac.jp.
authors.forename: Akio
authors.initials: A
authors.lastname: Oishi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kojima
authors.forename: Michiko
authors.initials: M
authors.lastname: Mandai
authors.forename: Shigeru
authors.initials: S
authors.lastname: Honda
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Matsuoka
authors.forename: Hideyasu
authors.initials: H
authors.lastname: Oh
authors.forename: Mihori
authors.initials: M
authors.lastname: Kita
authors.forename: Tomoko
authors.initials: T
authors.lastname: Nagai
authors.forename: Masashi
authors.initials: M
authors.lastname: Fujihara
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Bessho
authors.forename: Mamoru
authors.initials: M
authors.lastname: Uenishi
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Kurimoto
authors.forename: Akira
authors.initials: A
authors.lastname: Negi
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015862:Choroid Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D004396:Coloring Agents; D004311:Double-Blind Method; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D007208:Indocyanine Green; D058449:Intravitreal Injections; D008297:Male; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011127:Polyps / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D011166:Porphyrins / Q000627:therapeutic use*; D011446:Prospective Studies; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D004396:Coloring Agents; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D007208:Indocyanine Green; D000069579:Ranibizumab